Lupin launches generic seizure drug in U.S.

Lupin has launched Topiramate Extended-Release capsules, in different strengths, in the United States.

Bioequivalent to Supernus Pharmaceuticals’ Trokendi XR capsules and indicated for the treatment of certain types of seizures, the product launch follows U.S. FDA approval for Lupin’s abbreviated new drug application. Topiramate ER capsules had an estimated annual sale of $164 million in the U.S., the company said, citing IQVIA MAT Dec 2025 numbers.

Lupin shares closed 1.04% higher at ₹2,217.40 each on the BSE on Thursday.